Disease Progression Following Imatinib Failure in Gastrointestinal Stromal Tumors: Role of Surgical Therapy

2007 ◽  
Vol 12 (4) ◽  
pp. 438-442 ◽  
Author(s):  
Faek R. Jamali ◽  
Sophie S. Darwiche ◽  
Nizar El‐Kinge ◽  
Ayman Tawil ◽  
Assaad M. Soweid
Keyword(s):  
Disease Progression ◽  
Surgical Therapy ◽  
Gastrointestinal Stromal Tumors ◽  
Stromal Tumors

scholarly journals Clinical Overview of GIST and Its Latest Management by Endoscopic Resection in Upper GI: A Literature Review

2018 ◽  
Vol 2018 ◽  
pp. 1-9 ◽  
Author(s):  
Cicilia Marcella ◽  
Rui Hua Shi ◽  
Shakeel Sarwar
Keyword(s):  
Endoscopic Resection ◽  
Gastrointestinal Stromal Tumors ◽  
En Bloc Resection ◽  
Bloc Resection ◽  
En Bloc ◽  
Endoscopic Techniques ◽  
Stromal Tumors ◽  
Upper Gi ◽  
Risk Of Malignancy

Aims. To review the clinical presentation, diagnosis, assessment of risk of malignancy, and recent advances in management (mainly focusing on the role of endoscopic resection) of gastrointestinal stromal tumors (GISTs) in upper GI.Method. We searched Embase, Web of science, and PubMed databases from 1993 to 2018 by using the following keywords: “gastrointestinal stromal tumors,” “GIST,” “treatment,” and “diagnosis.” Additional papers were searched manually from references of the related articles.Findings. The improvement of endoscopic techniques in treating upper gastrointestinal subepithelial tumors especially gastrointestinal tumors has reduced the need for invasive surgery in patients unfit for surgery. Many studies have concluded that modified endoscopic treatments are effective and safe. These treatments permit minimal tissue resection, better dissection control, and high rates of en bloc resection with an acceptable rate of complications.

scholarly journals Role of PLK1 signaling pathway genes in gastrointestinal stromal tumors

2018 ◽  
Author(s):  
Jen‑Shi Chen ◽  
Chun‑Nan Yeh ◽  
Chi‑Tung Cheng ◽  
Chueh‑Chuan Yen ◽  
Yen‑Yang Chen ◽  
...  
Keyword(s):  
Signaling Pathway ◽  
Gastrointestinal Stromal Tumors ◽  
Stromal Tumors

Outcome Following Surgical Therapy for Gastrointestinal Stromal Tumors

2006 ◽  
Vol 10 (8) ◽  
pp. 1099-1105 ◽  
Author(s):  
M GUPTA ◽  
B SHEPPARD ◽  
C CORLESS ◽  
K MACDONELL ◽  
C BLANKE ◽  
...  
Keyword(s):  
Surgical Therapy ◽  
Gastrointestinal Stromal Tumors ◽  
Stromal Tumors

scholarly journals The role of FBXW7, a cell-cycle regulator, as a predictive marker of recurrence of gastrointestinal stromal tumors

2019 ◽  
Vol 22 (6) ◽  
pp. 1100-1108
Author(s):  
Yuki Koga ◽  
Masaaki Iwatsuki ◽  
Kohei Yamashita ◽  
Yuki Kiyozumi ◽  
Junji Kurashige ◽  
...  
Keyword(s):  
Cell Cycle ◽  
Gastrointestinal Stromal Tumors ◽  
Predictive Marker ◽  
Stromal Tumors ◽  
Cell Cycle Regulator ◽  
A Cell

Blood neutrophil-to-lymphocyte ratio is associated with prognosis in advanced gastrointestinal stromal tumors treated with imatinib

2018 ◽  
Vol 104 (6) ◽  
pp. 415-422 ◽  
Author(s):  
Piotr Rutkowski ◽  
Paweł Teterycz ◽  
Anna Klimczak ◽  
Elżbieta Bylina ◽  
Katarzyna Szamotulska ◽  
...  
Keyword(s):  
Disease Progression ◽  
Gastrointestinal Stromal Tumors ◽  
Proportional Hazards Model ◽  
Cox Proportional Hazards Model ◽  
Neutrophil To Lymphocyte Ratio ◽  
Rank Test ◽  
Imatinib Treatment ◽  
Stromal Tumors ◽  
Lymphocyte Ratio ◽  
Advanced Gist

Introduction: Neutrophil-to-lymphocyte ratio (NLR) was shown to be prognostic in several solid malignancies. There are limited data about predictive/prognostic value of NLR during targeted therapy of patients with advanced gastrointestinal stromal tumors (GIST). The aim of this study was to asses a clinical value of this ratio in patients with advanced GIST. Methods: Between 2001 and 2016, 385 patients with metastatic/unresectable GIST treated initially with imatinib were included in the analysis. In all patients, the NLR was assessed at the baseline, after 3 months of treatment, and upon disease progression (or last observation). The cutoff values for NLR were set at 2.7 and 5.4. Kaplan-Meier survival probability estimation with log-rank test and Cox proportional hazards model were used for analysis. Results: Median progression-free survival (PFS) on imatinib treatment was 44.8 months, 5-year rate 43%; median overall survival (OS) 87.2 months, 10-year rate 36.3%. NLR >2.7 at baseline was significantly associated with poorer OS and PFS: median OS was 89.3 months (95% confidence interval [CI] 80.2-115) for NLR ratio ≤2.7 vs 59.4 months (95% CI 48.6-82) for NLR >2.7 ( p < .001); median PFS was 59.4 vs 32.7 ( p < .001), respectively. In multivariate model adjusted for mitotic index and driver mutation in the tumor ( KIT exon 11 mutation versus other), NLR ratio was proven to be statistically significant (hazard ratio 1.09; 95% CI 1.01-1.19; p = .030). Among patients with disease progression, NLR >2.7 assessed at the third month of treatment was linked with significantly shorter median time to progression (7.5 vs 19 months). Conclusions: Our results demonstrate the usefulness of NLR as a prognostic and predictive marker as well as a marker for treatment monitoring in patients with advanced GIST treated with imatinib.

Sign in / Sign up

Export Citation Format

Share Document